重组人血管内皮抑制素可抑制兔耳增生性瘢痕

背景：增生性瘢痕局部血流量明显增高，微血管密度明显高于萎缩期及成熟的正常瘢痕。 目的：观察重组人血管内皮抑制素对新西兰大耳兔兔耳增生性瘢痕的抑制作用及其对瘢痕中血管内皮生长因子的作用。 方法：建立兔耳增生性瘢痕动物模型。随机分为2组，实验组局部注射重组人血管内皮抑制素，对照组局部注射生理盐水。 结果与结论：药物干预后30 d实验组兔耳瘢痕较对照组颜色变淡、质地柔软、厚度薄。苏木精-伊红染色实验组真皮层较对照组薄，单位面积内成纤维细胞数较对照组少，呈平行排列，毛细血管管径较对照组细；实验组瘢痕增生指数显著低于对照组(P < 0.01)。实验组瘢痕组织血管内皮生长因子阳性表达量显著低于对照组(P < 0.01)。说明重组人血管内皮抑制素注射液可能通过降低血管内皮生长因子蛋白的表达，从而抑制兔耳增生性瘢痕组织增生。

Recombinant human vascular endostatin inhibits hyperplastic scar of rabbit ears

BACKGROUND: Current treatments of hyperplastic scar are poor and limited, so it is necessary to seek a new effective drug to treat the hyperplastic scar. OBJECTIVE: To investigate the effect of recombinant human endostatin injection on hyperplastic scars of New Zealand big-eared rabbit ears. METHODS: 16 New Zealand big-eared rabbit were used to establish hyperplastic scar animal models and then the rabbits were randomly divided into an experimental group and a control group with 8 rabbits in each group. After epithelialization of rabbit ear wound, rabbits in the experimental group were injected with recombinant human endostatin, and those in the control group were injected with physiological saline. After 30 days, changes in hyperplastic scar were observed and hematoxylin-eosin staining was performed to investigate the expression of vascular endothelial growth factor in the scar tissue by immunohistochemisty. RESULTS AND CONCLUSION: At 30 days after intervention, the scar tissue color became weaker, texture was softer, and scar thickness was thinner in the experimental group than in the control group. Hematoxylin-eosin staining showed that compared with the control group, dermis was thinner, fibroblasts in unit area were fewer, exhibiting a parallel arrangement, and capillary caliber was smaller in the experimental group. The hyperplastic scar index was significantly lower in the experimental group than in the control group (P < 0.01). Vascular endothelial growth factor positive expression in the experimental group was significantly lower than that in the control group (P < 0.01). These findings suggest that recombinant human endostatin injection maybe a better choice for treating hyperplastic scar by decreasing vascular endothelial growth factor protein expression.